Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cleveland Clinic Florida
With
Astellas Pharma US, Inc.
Women with mixed incontinence with primary stress symptoms undergoing Sub-Urethral Sling Procedures will be randomized to peri-operative placebo or solifenacin. Subjects in the placebo group will take orally once daily for 9 weeks. Subjects in the Solifenacin group will take orally once daily for 9 weeks.
Age
18–100
Sex
FEMALE
Healthy volunteers
Accepted
You may be eligible if
Age \>/= 18
Patient is appropriate for sub-urethral sling procedure
Mixed urinary incontinence
No antimuscarinic therapy for previous 30 days
You may not be if
Uncontrolled narrow angle glaucoma
Acute cystitis
Unevaluated hematuria
Currently using anti-muscarinic therapy
Unable to complete pre-operative urodynamics
Contraindication to anti-cholinergic therapy
Unable or unwilling to complete diaries or quality of life questionaire
